Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common painkiller tested against rare brain tumors

NCT ID NCT03079999

Disease control Sponsor: Massachusetts Eye and Ear Infirmary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether aspirin can delay tumor growth and maintain hearing in people with vestibular schwannoma (acoustic neuroma), a non-cancerous brain tumor. About 97 participants are randomly assigned to take aspirin or a placebo twice daily. The study tracks how long it takes for the tumor to grow more than 20%.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aspirin
What this could lead to
If it works, aspirin could offer a simple, low-cost way to slow tumor growth and protect hearing in people with vestibular schwannomas.
What could go wrong
This is a mid-stage trial with only 97 participants, so results may not be conclusive. Aspirin also carries risks like stomach bleeding, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

97 people

The number who actually took part.

Started

Jun 2018

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Radiographic diagnosis of vestibular schwannoma (NF2-associated or sporadic). * Age≥12 years. * Ability to provide informed consent.Pediatric patients must provide assent in addition to their parents'/guardians' consent. Adult patients who cannot consent for themselves will not be eligible to participate in this study. * Ability to swallow tablets. Exclusion Criteria: * Inability to perform volumetric measurements of vestibular schwannoma(s). * Inability to tolerate MRI with contrast. * Daily use of aspirin within the last two months. Occasional use of aspirin for pain relief is not exclusionary. * Known allergy to aspirin. * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of aspirin. * Pregnant or lactating women. * Patients with serious medical illnesses (e.g. severe asthma) that in the option of the investigator could prevent participation in the trial. * Active bleeding diathesis. * Hydrocephalus from brainstem compression. * Febrile illness or flu-like illness in children and adolescents less than 18 years of age.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acoustic neuroma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acoustic neuroma Neurofibromatosis 2 NF2-related schwannomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acoustic neuroma Neurofibromatosis 2 Vestibular schwannoma

Contacts and locations

Locations

  • Massachusetts Eye and Ear

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Stanford Otolaryngology/HNS

    Stanford, California, 94304, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Utah

    Salt Lake City, Utah, 84101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.